Literature DB >> 6548674

Significance of the endogenous digoxin-like substance in infants and mothers.

G Koren, D Farine, D Maresky, J Taylor, J Heyes, S Soldin, S MacLeod.   

Abstract

Digoxin serum concentrations were measured by a routine radioimmunoassay in 30 neonates not receiving digoxin; nonetheless, digoxin levels were between 0.17 nM and 1.64nM (means = 0.64nM +/- 0.27 nM). There was a negative correlation between gestational age and concentration of an endogenous digoxin-like substance (EDLS). Neonates less than or equal to 32 wk gestational age had higher levels of EDLS than neonates greater than 32 wk old. EDLS concentrations were compared in 22 mothers and their 24 offspring and were higher in all newborn infants (0.34nM +/- 0.09nM and 0.15nM +/- 0.08nM). EDLS was shown to inhibit Na+-K+-adenosinetriphosphatase activity by measurement of 86Rb uptake in erythrocytes exposed to sera samples from 30 infants in the study. EDLS levels greater than 0.6 ng/ml were associated with lesser 86Rb uptake. Simulation kinetics suggest that the presence of 0.6nM EDLS would lengthen the digoxin t1/2 by 64%, reduce the volume of distribution by 23%, and lower clearance by 53% if the peak "true" digoxin level were 2 ng/ml. EDLS concentrations of 1.5 ng/ml would increase the t1/2 by 207% while reducing the volume of distribution by 43% and clearance by 81%. These considerations cast serious doubts on the validity of currently accepted digoxin kinetics and dosing in preterm infants.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6548674     DOI: 10.1038/clpt.1984.254

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Endogenous factors with immunological and biological activity similar to cardiac glycosides: biochemical and pathophysiological implications.

Authors:  A Clerico; G Mariani
Journal:  J Endocrinol Invest       Date:  1992-05       Impact factor: 4.256

Review 2.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

Review 3.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Endogenous digoxin-like immunoreactivity during pregnancy and at birth.

Authors:  J M Lupoglazoff; E Jacqz-Aigrain; B Guyot; O Chappey; P Blot
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

Review 5.  The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation.

Authors:  G M Mitani; I Steinberg; E J Lien; E C Harrison; U Elkayam
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

6.  Digoxin concentration in saliva and plasma in infants, children, and adolescents with heart disease.

Authors:  Eli Zalzstein; Nili Zucker; Matityhau Lifshitz
Journal:  Curr Ther Res Clin Exp       Date:  2003-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.